Аннотация:Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Europe and remains incurable. Targeted therapies have revolutionized the treatment of CLL, but many patients develop resistance, have severe side effects or relapse during treatment. In order to prevent ineffective treatment and toxic effects, there is an unmet clinical need for tailoring optimal therapy for each patient. The ERA PerMed project CLL-CLUE will identify novel biomarkers and implement artificial intelligence-based clinical decision support systems to guide treatment decisions. We expect that this will lead to significantly increased treatment efficacy, individualization of therapy and reduced drug use and side effects. In addition, reduced consumption of drugs and cost-effective outcomes will lower financial stress that the health care providers and patients experience. The proposed project will be carried out as a collaborative effort including leading clinical and molecular research groups in CLL in Europe, together with key competence in development of artificial intelligence-based decision support system for blood cancer patients and health economic evaluation in Europe. Here we present the Data Management Plan for the CLL-CLUE consortium. Data sharing between the trans-European project partners is governed by the General Data Protection Regulation (GDPR) and the Data Access Agreement (DAA) between the partners.
